PMID- 36669964 OWN - NLM STAT- MEDLINE DCOM- 20230306 LR - 20230417 IS - 1873-2518 (Electronic) IS - 0264-410X (Print) IS - 0264-410X (Linking) VI - 41 IP - 11 DP - 2023 Mar 10 TI - Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022. PG - 1859-1863 LID - S0264-410X(23)00016-6 [pii] LID - 10.1016/j.vaccine.2022.12.069 [doi] AB - BACKGROUND: COVID-19 vaccines may be co-administered with other recommended vaccines, including seasonal influenza vaccines. However, few studies have evaluated the safety of co-administration of mRNA COVID-19 and seasonal influenza vaccines. OBJECTIVE: To describe reports to the Vaccine Adverse Event Reporting System (VAERS) after co-administration of mRNA COVID-19 and seasonal influenza vaccines. METHODS: We searched the VAERS database for reports of adverse events (AEs) following co-administration of mRNA COVID-19 and seasonal influenza vaccines and following a first booster dose mRNA COVID-19 vaccine alone, during July 1, 2021-June 30, 2022. We assessed the characteristics of these reports and described the most frequently reported MedDRA preferred terms (PTs). Clinicians reviewed available medical records for serious reports and reports of adverse events of special interest (AESI) and categorized the main diagnosis by system organ class. RESULTS: From July 1, 2021 through June 30, 2022, VAERS received 2,449 reports of adverse events following co-administration of mRNA COVID-19 and seasonal influenza vaccines. Median age of vaccinees was 48 years (IQR: 31, 66); 387 (15.8%) were classified as serious. Most reports (1,713; 69.3%) described co-administration of a first booster dose of an mRNA COVID-19 vaccine with seasonal influenza vaccine. The most common AEs among non-serious reports were injection site reactions (193; 14.5%), headache (181; 13.6%), and pain (171; 12.8%). The most common AEs among reports classified as serious were dyspnea (38; 14.9%), COVID-19 infection (32; 12.6%), and chest pain (27; 10.6%). DISCUSSION: This review of reports to VAERS following co-administration of mRNA COVID-19 and seasonal influenza vaccines did not reveal any unusual or unexpected patterns of AEs. Increased reporting of certain events (e.g., COVID-19 disease) was expected. CDC will continue to monitor the safety of co-administration of mRNA COVID-19 and seasonal influenza vaccines, including co-administration involving bivalent mRNA COVID-19 booster vaccines that have been recommended for people ages >/= 6 months in the United States. CI - Published by Elsevier Ltd. FAU - Moro, Pedro L AU - Moro PL AD - Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. Electronic address: pmoro@cdc.gov. FAU - Zhang, Bicheng AU - Zhang B AD - Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Ennulat, Carol AU - Ennulat C AD - Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Harris, Margaret AU - Harris M AD - Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - McVey, Rachel AU - McVey R AD - Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Woody, Gina AU - Woody G AD - Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Marquez, Paige AU - Marquez P AD - Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - McNeil, Michael M AU - McNeil MM AD - Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. FAU - Su, John R AU - Su JR AD - Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia. LA - eng PT - Journal Article PT - Review DEP - 20230109 PL - Netherlands TA - Vaccine JT - Vaccine JID - 8406899 RN - 0 (Influenza Vaccines) RN - 0 (COVID-19 Vaccines) RN - 0 (Vaccines, Inactivated) RN - 0 (RNA, Messenger) SB - IM MH - Humans MH - United States/epidemiology MH - Infant MH - *Influenza Vaccines/adverse effects MH - COVID-19 Vaccines/adverse effects MH - Vaccines, Inactivated MH - Adverse Drug Reaction Reporting Systems MH - Seasons MH - *COVID-19/prevention & control MH - *Influenza, Human/prevention & control MH - RNA, Messenger PMC - PMC9826985 OTO - NOTNLM OT - Adverse events OT - COVID-19 OT - Co-administration OT - Coronavirus OT - Epidemiology OT - Influenza vaccines OT - SARS-CoV-2 OT - Surveillance OT - Vaccine safety OT - mRNA vaccines COIS- Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2023/01/21 06:00 MHDA- 2023/03/07 06:00 PMCR- 2023/01/09 CRDT- 2023/01/20 22:02 PHST- 2022/11/30 00:00 [received] PHST- 2022/12/23 00:00 [revised] PHST- 2022/12/25 00:00 [accepted] PHST- 2023/01/21 06:00 [pubmed] PHST- 2023/03/07 06:00 [medline] PHST- 2023/01/20 22:02 [entrez] PHST- 2023/01/09 00:00 [pmc-release] AID - S0264-410X(23)00016-6 [pii] AID - 10.1016/j.vaccine.2022.12.069 [doi] PST - ppublish SO - Vaccine. 2023 Mar 10;41(11):1859-1863. doi: 10.1016/j.vaccine.2022.12.069. Epub 2023 Jan 9.